Zemprocitinib, new JAK1 inhibitor, reaches major clinical milestone
Zemprocitinib, a selective JAK1 inhibitor, achieves clinical trial endpoints in treating conventional therapy-resistant rheumatoid arthritis.
Published 7sem·1 sourceNotable·updated 4h
The fact
This clinical milestone represents significant progress for patients unresponsive to current treatments.
The compound opens new therapeutic perspectives for managing severe forms of this autoimmune disease.
🔗Click the link to read an article on the topic:
What if you saw the whole news differently?Factae cross-checks hundreds of sources worldwide to keep only the fact, no opinion. Explore the front page.→Story timeline
Jun 18Zemprocitinib, new JAK1 inhibitor, reaches major clinical milestonethis article